行情

CEMI

CEMI

Chembio诊断
NASDAQ

实时行情|Nasdaq Last Sale

7.10
+0.13
+1.87%
盘后: 7.10 0 0.01% 16:00 09/20 EDT
开盘
6.78
昨收
6.97
最高
7.16
最低
6.78
成交量
8.27万
成交额
--
52周最高
10.79
52周最低
4.390
市值
1.25亿
市盈率(TTM)
-9.9649
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CEMI 新闻

  • 法国财长:若美国制裁欧盟 欧盟将反击
  • 央视.2天前
  • 隔夜要闻:美股涨跌不一 微软盘中刷新历史新高
  • 新浪美股.2天前
  • 中概股周四收平 流利说连跌三天股价创纪录新低
  • 新浪美股.2天前
  • 市场聚焦沙特供应短缺 美油涨逾1%暂止颓势
  • 汇通网.2天前

更多

所属板块

制药
+1.04%
制药与医学研究
+0.95%

热门股票

名称
价格
涨跌幅

CEMI 简况

Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company's products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format and a barrel format. Its HIV 1/2 rapid antibody detection test incorporates the Dual Path Platform (DPP) POCT technology. The DPP HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples, as well as in all blood matrices. The Company's product pipeline includes a multiplex rapid test for earlier detection of HIV and a multiplex test that detects HIV and Syphilis specific antibodies.
展开

Webull提供Chembio Diagnostics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。